In the present study, we are the first to investigate the role and prognostic value of CDK2AP1 in a clinical setting of large cohort of PCa patients treated non-surgically by transurethral resection of the prostate (TURP) including incidental, advanced and castrate-resistant prostate cancer (CRPC). Here, CDK2AP1 is linked to posterior cortical atrophy.